Welcome to our dedicated page for Scworx SEC filings (Ticker: WORX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SCWorx Corp. filings document the regulatory record for a healthcare SaaS data management company and its common stock. The company’s 8-K reports cover Nasdaq minimum-bid-price notices, reverse stock split actions, warrant inducement agreements, and other material events tied to capital structure and listing compliance.
Its registration and proxy filings describe securities offerings, common stock and warrant issuance, shareholder voting matters, director elections, executive compensation advisory votes, auditor ratification, and Nasdaq Rule 5635(d) share-issuance approvals. These disclosures also frame governance, capital authorization, and financing terms for the business.
SCWorx Corp. is asking shareholders at its July 22, 2026 annual meeting to elect four directors, approve executive pay on an advisory basis, ratify Astra Audit & Advisory as auditor for 2026, and authorize a potential reverse stock split.
The reverse split, at a ratio between 1‑for‑1.5 and 1‑for‑10, would be used on an “as needed” basis to help lift the share price to at least $1.00 and support efforts to regain a Nasdaq Capital Market listing. SCWorx currently has 1,066,918 common shares and 39,810 Series A preferred shares outstanding as of June 9, 2026, with each common and as‑converted preferred share entitled to one vote.
SCWorx Corp. proposes standard annual meeting items and seeks shareholder approval for a discretionary reverse stock split. The proxy solicits votes to elect four directors, approve executive compensation on a non-binding basis, ratify Astra Audit & Advisory, LLC as auditor, and approve an amendment permitting a reverse stock split in a ratio between 1-for-1.5 and 1-for-10 to target a minimum $1.00 bid price under Nasdaq Rule 5550(a)(2). The Board notes prior Nasdaq delisting actions in April 2026 and describes procedures for implementing a split if approved.
The proxy discloses governance details (committee composition and meeting frequency), executive and director compensation summaries, related-party advances and audit fees, and instructions for voting by proxy or in person at the meeting planned for July __, 2026.
SCWorx Corp. reports Q1 2026 results with modest revenue growth and a sharply reduced loss. Revenue was $744,899, up slightly from $720,299 a year earlier. Cost of revenue dropped to $370,790, lifting gross profit to $374,109 from $136,863.
Operating expenses rose to $509,923, mainly from higher salaries and new stock-based compensation, but interest expense fell as all prior convertible notes were converted to equity. Net loss narrowed to $173,767 from $476,303. Cash was $1.34 million at March 31, 2026, down from $1.64 million at year-end.
The company implemented a 1-for-15 reverse stock split effective April 10, 2026. Nasdaq has notified SCWorx that its shares will be delisted for failing to meet the $1.00 minimum bid price; trading was suspended April 14, 2026, and the company has appealed. Management also reports that disclosure controls and procedures were not effective due to control design deficiencies and lack of segregation of duties.
SCWorx Corp. Schedule 13G/A (Amendment No. 5) reports holdings by Iroquois Capital Management LLC, Iroquois Master Fund Ltd., Iroquois Capital Investment Group LLC, and related reporting persons Richard Abbe and Kimberly Page. The cover pages give effected share counts and percentages as of March 31, 2026 based on 15,999,423 shares outstanding. The filing explains large warrant positions that are subject to Beneficial Ownership Blockers (4.99% and 9.99%), which limit exercise so the reported percentages reflect those blockers. The cover-page rows show dispositive and voting powers for each reporting person and provide percentages that give effect to the blockers.
SCWorx Corp. received notice from Nasdaq on April 7, 2026 that its common stock will be delisted from the Nasdaq Capital Market for failing to meet the minimum bid price requirement of $1.00 per share under Nasdaq Rule 5550(a)(2) by the April 6, 2026 deadline.
Nasdaq plans to suspend trading on April 14, 2026 and file a Form 25-NSE to remove the stock from listing and registration, though SCWorx has appealed this determination to a Nasdaq hearings panel. To address the deficiency, the company amended its certificate of incorporation to implement a 1-for-15 reverse stock split, combining every 15 outstanding shares into one share, effective at the open of trading on April 10, 2026.
To regain compliance, the post-split common stock must trade at or above $1.00 per share for ten consecutive trading days. The company states it expects to regain compliance as a result of the reverse split but cautions there is no assurance it will succeed or prevail in its appeal, and that failure to remain listed on Nasdaq could adversely affect the company.
SCWorx Corp. has approved a 1-for-15 reverse stock split of its common stock by amending its certificate of incorporation. Every 15 shares of outstanding common stock will be combined into one share. The reverse split is expected to be effective at the start of trading on April 10, 2026.
The company is undertaking this reverse split to help regain compliance with the Nasdaq Stock Market’s minimum bid price rule, which requires its common stock to trade at or above $1.00 per share for ten consecutive trading days. SCWorx notes there is no assurance this step will restore compliance, and if compliance is not regained, its common stock will be delisted from Nasdaq.
SCWorx Corp. reports declining 2025 results and growing financial strain. Revenue slipped about 4% to $2,877,629 from $2,989,599 in 2024, while net loss widened sharply to $4,444,109 from $1,136,225. The company reports an accumulated deficit of $35,420,175 and acknowledges substantial doubt about its ability to continue as a going concern, citing ongoing losses and challenges raising capital.
At December 31, 2025, SCWorx had 9 employees and focuses on SaaS data-normalization and interoperability solutions for U.S. hospitals. As of June 30, 2025, non‑affiliate market value was about $2.7 million, and as of March 31, 2026 there were 15,999,423 common shares outstanding, with 54,055,187 shares issuable under warrant agreements. The company is working to regain Nasdaq’s $1.00 minimum bid price and may implement a reverse stock split if needed.
SCWorx Corp. investors Iroquois Capital Management, Richard Abbe, and Kimberly Page report their beneficial ownership of the company’s common stock in an amended Schedule 13G as of December 31, 2025. Iroquois Capital Management and Kimberly Page each report beneficial ownership of 960,140 shares, representing 5.7% of the class. Richard Abbe reports beneficial ownership of 1,153,662 shares, or 6.8% of the class.
These positions include shares issuable from warrants and convertible notes that are subject to 4.99% and 9.99% Beneficial Ownership Blockers, which limit how much can be converted or exercised at any time. The reported percentages are calculated using 15,826,834 shares outstanding as of September 30, 2025. The filers state the securities are not held to change or influence control of SCWorx.
SCWorx Corp. is registering 53,220,845 shares of common stock for resale by existing investors, tied to prior convertible notes and warrant financings. The company will not receive proceeds from these resale transactions, but could receive up to approximately $16.5 million if related warrants are exercised for cash. SCWorx had 15,826,834 common shares outstanding as of January 6, 2026, while a large pool of additional shares is issuable under outstanding warrants, creating substantial potential dilution.
The filing highlights a weak financial position: 2024 revenue fell about 21% to $2,989,599, with a 2024 net loss of $1,136,225 and an accumulated deficit of $30,976,066 at year-end. For the nine months ended September 30, 2025, the company lost $3,694,927, used about $1,414,534 in operating cash, and held only $684,000 of cash, leading auditors to express substantial doubt about its ability to continue as a going concern.
The prospectus also discloses a Nasdaq minimum bid price deficiency. SCWorx has until April 6, 2026 to regain compliance, likely via a reverse stock split, and warns that failure, especially combined with significant warrant overhang, could result in delisting and make future capital raises more difficult.